Cargando…

Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe

Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in our cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ternák, Gábor, Berényi, Károly, Kun, Szilárd, Szigeti, Nóra, Decsi, Tamás, Sütő, Gábor, Wittmann, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373876/
https://www.ncbi.nlm.nih.gov/pubmed/34408224
http://dx.doi.org/10.1038/s41598-021-96301-y
_version_ 1783739996667117568
author Ternák, Gábor
Berényi, Károly
Kun, Szilárd
Szigeti, Nóra
Decsi, Tamás
Sütő, Gábor
Wittmann, István
author_facet Ternák, Gábor
Berényi, Károly
Kun, Szilárd
Szigeti, Nóra
Decsi, Tamás
Sütő, Gábor
Wittmann, István
author_sort Ternák, Gábor
collection PubMed
description Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in our cells, and other bacteria share many common enzymes including beta-lactamases and it is supported by evidence that some beta-lactamase inhibitors are able to interact with counterpart enzymes. Thus, antibiotics may utilize two different pathways influencing the development of T1DM; one through modulation of microbiome and a second one via the interaction of mitochondrial enzymes. Data of consumption of penicillin (both narrow and broad spectrum) and beta-lactamase inhibitors in 30 European countries were collected from the database of the European Centre for Disease Prevention and Control. These data were correlated with the prevalence reported by the International Diabetes Federation (2019) referring to type 1 diabetes in Europe. No correlation was found between total penicillin consumption or use of broad spectrum penicillin and the prevalence of type 1 diabetes. Nevertheless, broad spectrum penicillin, in combination with beta-lactamase inhibitor, was in inverse correlation with the prevalence of type 1 diabetes (r = − 0.573, p = 0.001). On the other hand, narrow spectrum penicillin was in positive correlation with type 1 diabetes (r = 0.523, p = 0.003). Prevalence of type 1 diabetes showed an inverse correlation with the use of beta-lactamase inhibitors and a positive one with that of narrow spectrum penicillin. Such a detailed analysis has not so far been provided referring to the penicillin group. In the background of this association either microbiomal or direct mitochondrial effects can be supposed.
format Online
Article
Text
id pubmed-8373876
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83738762021-08-19 Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe Ternák, Gábor Berényi, Károly Kun, Szilárd Szigeti, Nóra Decsi, Tamás Sütő, Gábor Wittmann, István Sci Rep Article Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in our cells, and other bacteria share many common enzymes including beta-lactamases and it is supported by evidence that some beta-lactamase inhibitors are able to interact with counterpart enzymes. Thus, antibiotics may utilize two different pathways influencing the development of T1DM; one through modulation of microbiome and a second one via the interaction of mitochondrial enzymes. Data of consumption of penicillin (both narrow and broad spectrum) and beta-lactamase inhibitors in 30 European countries were collected from the database of the European Centre for Disease Prevention and Control. These data were correlated with the prevalence reported by the International Diabetes Federation (2019) referring to type 1 diabetes in Europe. No correlation was found between total penicillin consumption or use of broad spectrum penicillin and the prevalence of type 1 diabetes. Nevertheless, broad spectrum penicillin, in combination with beta-lactamase inhibitor, was in inverse correlation with the prevalence of type 1 diabetes (r = − 0.573, p = 0.001). On the other hand, narrow spectrum penicillin was in positive correlation with type 1 diabetes (r = 0.523, p = 0.003). Prevalence of type 1 diabetes showed an inverse correlation with the use of beta-lactamase inhibitors and a positive one with that of narrow spectrum penicillin. Such a detailed analysis has not so far been provided referring to the penicillin group. In the background of this association either microbiomal or direct mitochondrial effects can be supposed. Nature Publishing Group UK 2021-08-18 /pmc/articles/PMC8373876/ /pubmed/34408224 http://dx.doi.org/10.1038/s41598-021-96301-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ternák, Gábor
Berényi, Károly
Kun, Szilárd
Szigeti, Nóra
Decsi, Tamás
Sütő, Gábor
Wittmann, István
Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_full Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_fullStr Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_full_unstemmed Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_short Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_sort inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in europe
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373876/
https://www.ncbi.nlm.nih.gov/pubmed/34408224
http://dx.doi.org/10.1038/s41598-021-96301-y
work_keys_str_mv AT ternakgabor inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
AT berenyikaroly inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
AT kunszilard inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
AT szigetinora inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
AT decsitamas inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
AT sutogabor inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
AT wittmannistvan inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope